← All trials
NCT04301349
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 15, 2020
- Primary completion
- Jun 15, 2020
- Completion date
- Jun 30, 2020
- First posted
- Mar 10, 2020
- Last posted
- Mar 10, 2020
- Enrollment
- 200
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Cairo UniversityLead sponsor
- Cairo UniversityOverall official - principal investigator
- Cairo UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.